The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST).
 
Jamie Chaft
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Exact Sciences; Foundation Medicine; Genentech/Roche; Lilly; Merck; Natera; Nuvation Bio; Revolution Medicines
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Boehringer Ingelheim; Lilly; Merck
 
Zhuoxin Sun
No Relationships to Disclose
 
Charles Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Auron Therapeutics; Daiichi Sankyo/UCB Japan; DISCO; Earli; Genentech/Roche; Jazz Pharmaceuticals; Merck
Research Funding - Daiichi Sankyo (Inst); Merck (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Royalties related to licensing of anti-DLL3 antibodies.
 
Charles Simone
No Relationships to Disclose
 
Kurt Oettel
No Relationships to Disclose
 
David Kozono
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Genentech
 
Ramaswamy Govindan
No Relationships to Disclose
 
Jacob Sands
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; Fosun Pharma; Genentech/Roche; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Merck; Novartis; Pfizer; Sanofi; Summit Therapeutics
Research Funding - Amgen (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca
 
John Heymach
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; ALK Positive; ArriVent Biopharma; AstraZeneca; BioNtech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Lilly (Inst); Mirati Therapeutics; ModeX Therapeutics; Novartis; Ottimo Pharma; Regeneron; Sanofi/Aventis; Spectrum Pharmaceuticals; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics; Spectrum Pharmaceuticals; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations; Patents pending regarding classification of EGFR mutations; Patents pending regarding subtyping of SCLC lung cancer.
 
Luis Raez
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Johnson & Johnson/Janssen; Lilly; Merck; Natera; Novocure
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Heat Biologics (Inst); Loxo (Inst); Merck (Inst); Merck Serono (Inst); NantHealth (Inst); Natera (Inst); Novartis (Inst); ONC4 (Inst); Pfizer (Inst); Syndax (Inst)
 
Shakun Malik
No Relationships to Disclose
 
Tom Stinchcombe
Consulting or Advisory Role - Boehringer Ingelheim; Coherus Biosciences; Gilead Sciences; Janssen Oncology; Pfizer; Takeda
Research Funding - Boehringer Ingelheim (Inst); Mirati Therapeutics (Inst); Nuvalent, Inc. (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Pfizer
Other Relationship - Genentech; GlaxoSmithKline; Merck; Pfizer
 
Sumithra Mandrekar
Consulting or Advisory Role - Harbinger Oncology, Inc
 
David Gerber
Stock and Other Ownership Interests - Gilead Sciences; Walgreens
Consulting or Advisory Role - Bayer; Catalyst Pharmaceuticals; Daichi Sankyo; Jazz Pharmaceuticals; Summit Therapeutics; Taiho Oncology
Research Funding - AstraZeneca (Inst); Novocure (Inst)
Patents, Royalties, Other Intellectual Property - Co-founder, Chief Scientific Officer, OncoSeer Diagnostics, LLC; Royalties from Oxford University Press from two books.; UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 4153 - US Patent Application 63/386,387 IMMUNOTHERAPY TOXICITY – CELL PHENOTYPES; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4287 – US Patent Application TBD INNATE AND ADAPTIVE IMMUNE FEATURES ASSOCIATED WITH TOXICITIES IN PATIENTS RECEIVING CHECKPOINT INHIBITOR THERAPY
Other Relationship - OncoSeer Diagnostics
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb
 
Jeffrey Bradley
Employment - University of Pennsylvania Abramson Cancer Center
Honoraria - Mevion Medical Systems
Consulting or Advisory Role - Mevion Medical Systems
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Genentech; IBA
 
Everett Vokes
Stock and Other Ownership Interests - Coordination Pharmaceuticals; McKesson
Honoraria - Ascendis Pharma (I); Guidepoint Inc (I); Vision2Voice (I)
Consulting or Advisory Role - Abbvie; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Day One Therapeutics; Delcath Systems; Eikon; EMD Serono; Foresight Diagnostics; Genmab; GlaxoSmithKline; Marengo Therapeutics; Merus; MJH Life Sciences; Translational Drug Development LLC
Research Funding - Abbvie; Alliance Pharma; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Novartis
 
David Gandara
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Foundation Medicine; Genentech (Inst); Guardant Health (Inst); Henlius (Inst); Henlius USA (Inst); Janssen; Merck; Mirati Therapeutics; Novartis; Oncohost (Inst); One Carbon (Inst); Regeneron
 
Charles Staley
Honoraria - Collegium
 
Suresh Ramalingam
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie
Other Relationship - American Cancer Society
 
Onkar Khullar
Consulting or Advisory Role - Merck; Roche